Proposal of Classification Criteria for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Disease Activity
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a rare chronic neuroinflammatory disease. While the disease usually progresses slowly without remission, there is a subgroup of patients with rapid progression and another subgroup with very slow progression. However, there have been no reports to date that have successfully determined the criteria to differentiate these subgroups. Therefore, we initially conducted a statistical modeling analysis to explore representative patterns of disease progression using data from our nationwide HAM/TSP patient registration system (“HAM-net”). The latent class mixed model analysis on the retrospective data (n=205) of disease progression measured by the change in Osame Motor Disability Score from the onset of the disease to diagnosis demonstrated three representative progression patterns of HAM/TSP. Next, to test the effect of the progression rate at the initial phase of the disease on long-term prognosis, we divided 312 “HAM-net” registered patients into three groups (rapid, slow, and very slow progressors) based on the progression rate, then analyzed long-term functional prognosis of each group using the Kaplan-Meier method. Our data clearly demonstrated that the rapid progression at the early phase of the disease is an important poor prognostic factor. Moreover, to determine the biomarkers capable of discriminating the difference in disease activity, we compared the value of potential biomarkers of HAM/TSP among rapid (n=15), slow (n=74), very slow (n=7), and controls (non-HAM/TSP patients, n=18). The cerebrospinal fluid (CSF) levels of neopterin and C-X-C motif chemokine 10 (CXCL10) were the most valuable markers to discriminate among rapid, slow, and very slow progressors. To differentiate between rapid and slow progressors, the cut-off values of neopterin and CXCL10 were determined to be 44 pmol/mL and 4400 pg/mL, respectively. Furthermore, to differentiate between slow and very slow progressors, these values were determined to be 5.5 pmol/mL and 320 pg/mL, respectively. Notably, we found that CSF levels of these markers in very slow progressors were within the reference range. Thus, we propose a new classification criteria for disease activity of HAM/TSP that may contribute to improving the treatment algorithm for HAM/TSP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Poiesz, B. J., Ruscetti, F. W., Gazdar, A. F., Bunn, P. A., Minna, J. D., & Gallo, R. C. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.12.7415 · Cited by 5,043
Therapeutic trials in 200 patients with HTLV-Iassociated myelopathy/tropical spastic paraparesis
Nakagawa, M., Nakahara, K., Maruyama, Y., Kawabata, M., Higuchi, I., Kubota, H., Izumo, S., Arimura, K., & Osame, M. (1996) · Journal of Neurovirology · doi:10.3109/13550289609146899 · Cited by 150
Yamano, Y., Araya, N., Sato, T., Utsunomiya, A., Azakami, K., Hasegawa, D., Izumi, T., Fujita, H., Aratani, S., Yagishita, N., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006517 · Cited by 140
Self-citationColer-Reilly, A. L. G., Sato, T., Matsuzaki, T., Nakagawa, M., Niino, M., Nagai, M., Nakamura, T., Takenouchi, N., Araya, N., Yagishita, N., et al. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0533-z · Cited by 39 · cited 1×
“Interestingly, a multicenter retrospective cohort study indicates that oral low-dose corticosteroid therapy reduces the progression rate of HAM/TSP and improves the longterm prognosis compared to untreated patients (Coler-Reilly et al., 2017).”
BackgroundSelf-citationNagai, M., Tsujii, T., Iwaki, H., Nishikawa, N., & Nomoto, M. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.0869 · Cited by 10
Cited by
Management of HAM/TSP: Systematic Review and Consensus-based Recommendations 2019
Araujo, A., Bangham, C. R. M., Casseb, J., Gotuzzo, E., Jacobson, S., Martin, F., Penalva de Oliveira, A., Puccioni-Sohler, M., Taylor, G. P., & Yamano, Y. (2021) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000000832 · Cited by 87
“The prognostic use of biomarkers of disease activity, especially CSF cytokines, has recently been published and may become an additional decision-making tool.(5)”
BackgroundInfluentialSelf-citationImmunovirological markers in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)
Enose-Akahata, Y., & Jacobson, S. (2019) · Retrovirology · doi:10.1186/s12977-019-0499-5 · Cited by 49
Tsutsumi, S., Sato, T., Yagishita, N., Yamauchi, J., Araya, N., Hasegawa, D., Nagasaka, M., Coler-Reilly, A. L. G., Inoue, E., Takata, A., et al. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1212-4 · Cited by 33
Self-citationYamauchi, J., Tanabe, K., Sato, T., Nakagawa, M., Matsuura, E., Tsuboi, Y., Tamaki, K., Sakima, H., Ishihara, S., Ohta, Y., et al. (2022) · Viruses · doi:10.3390/v14010136 · Cited by 31
Self-citationTamaki, K., Sato, T., Tsugawa, J., Fujioka, S., Yagishita, N., Araya, N., Yamauchi, J., Coler-Reilly, A. L. G., Nagasaka, M., Hasegawa, Y., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02110 · Cited by 29
“…can be classified into three groups according to disease activity, which is assessed on the basis of CSF concentrations of CXCL10 and neopterin (Sato et al., 2018b) Frontiers in Microbiology | www.frontiersin.org 9 September 2019 | Volume 10 | Article 2110 FIGURE 4 | Time course of motor…”
BackgroundSelf-citation
Metadata
- Authors
- Sato, T., Yagishita, N., Tamaki, K., Inoue, E., Hasegawa, D., Nagasaka, M., Suzuki, H., Araya, N., Coler-Reilly, A., Hasegawa, Y., Tsuboi, Y., Takata, A., & Yamano, Y.
- Venue
- Frontiers in Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2018-07-25
- Volume
- 9
- Pages
- 1651-1651
- ISSN
- 1664-302X (ISSN-L)
- OpenAlex
- W2875141779
- Cited by
- 68
- References
- 5
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Proposal of Classification Criteria for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Disease Activity. https://app.cochat.ai/papers/10.3389/fmicb.2018.01651
- The paper
- Sato, T., Yagishita, N., Tamaki, K., Inoue, E., Hasegawa, D., Nagasaka, M., Suzuki, H., Araya, N., Coler-Reilly, A., Hasegawa, Y., Tsuboi, Y., Takata, A., & Yamano, Y. (2018). Proposal of Classification Criteria for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Disease Activity. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2018.01651
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.